Welcome to our dedicated page for Perceptive Capital Solutions SEC filings (Ticker: PCSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Perceptive Capital Solutions Corp (PCSC) is a special purpose acquisition company in the Financial Services sector, listed on The Nasdaq Global Market under the ticker PCSC. It is described as a blank check company formed for the purpose of entering into a combination with one or more businesses or entities, with an intended focus on healthcare in the United States and other developed countries.
This SEC filings page is designed to help users review the regulatory record associated with PCSC’s SPAC activities. Although specific filings are not listed in the provided data, public communications indicate that PCSC’s securities were registered with the U.S. Securities and Exchange Commission in connection with its initial public offering of Class A ordinary shares. The registration statement for that offering was declared effective by the SEC, and the company notes that the offering was made only by means of a prospectus filed with the Commission.
In connection with its announced business combination with Freenome Holdings, Inc., PCSC has stated that it intends to file a registration statement on Form S-4 with the SEC. That filing is expected to include preliminary and definitive proxy statements for PCSC shareholders and a prospectus relating to the securities to be issued to Freenome’s stockholders. Additional information about the transaction is also expected to appear in a Current Report on Form 8-K filed by PCSC.
On this page, users can access PCSC’s historical and future SEC submissions, including registration statements, proxy materials and current reports that describe its SPAC structure, risk factors and the terms of its proposed business combination. AI-powered tools on the platform can assist in summarizing long-form documents, clarifying key sections in forms such as S-4 and 8-K, and highlighting information relevant to the evolution of PCSC’s capital structure and its transition to any combined company.
Freenome, Inc. director Scott Randal W. filed an initial statement of beneficial ownership, reporting common stock and stock option positions. He holds 12235.0000 Freenome common shares directly and 91969.0000 shares indirectly through Thinking Bench Capital, LLC, for which he disclaims beneficial ownership except for any pecuniary interest. He also reports several stock options over common stock, including an option over 71476.0000 shares at an exercise price of $2.83 expiring in 2028 and additional smaller grants with exercise prices from $8.45 to $18.24, some fully vested and others vesting in 48 equal monthly installments beginning in 2023 or 2024.
Freenome, Inc. reports that Chief Scientific Officer Lin Cheng-Ho Jimmy holds 410,154 shares of Common Stock directly, plus several stock options to acquire additional Common Stock at exercise prices ranging from 4.8500 to 18.2400, with expirations between 2029 and 2035. Certain options are fully vested, while others vest in monthly installments under service-based schedules; no new purchases or sales are reported.
Freenome, Inc. Chief Product Officer Ennis Riley Charles files an initial ownership report detailing his holdings of common stock and stock options. He reports direct ownership of common stock and additional shares held indirectly by the Riley Ennis Irrevocable Trust, for which he disclaims beneficial ownership except for any pecuniary interest.
The filing lists several stock options (rights to buy common stock) with exercise prices ranging from $4.8500 to $18.2400 and expirations between 2030 and 2035, including options that are fully vested and others that vest in monthly installments. One option’s exercise price will be automatically reduced to $8.45 upon certain events.
Freenome, Inc. reports that investment entities affiliated with Andreessen Horowitz have filed a Schedule 13G disclosing their beneficial ownership of the company’s common stock. The filing covers multiple Delaware limited partnerships and LLCs, as well as Marc L. Andreessen and Benjamin A. Horowitz.
The positions include 3,327,525 shares held by AH Bio Fund I, L.P., 1,038,814 shares held by Andreessen Horowitz LSV Fund II, L.P., 6,207 shares held by CLF Partners, LP, and 1,199,053 shares held by AH Parallel Fund IV, L.P., each with sole voting and dispositive power through their respective general partners. Based on 107,446,814 shares of common stock outstanding as of July 20, 2026, Marc Andreessen and Ben Horowitz are each reported as beneficially owning 5,571,599 shares, or 5.2% of the common stock, through their managing member roles in the general partner entities.
Freenome, Inc. has received FDA approval for SimpleScreen™ CRC, a blood-based screening test for colorectal cancer in adults aged 45 and older at average risk. The test analyzes cell-free DNA using AI/ML technology and was validated in the PREEMPT CRC study of more than 48,000 participants at over 200 sites.
In a prespecified analysis, SimpleScreen CRC showed 81.1% sensitivity for colorectal cancer, 13.7% sensitivity for advanced precancerous lesions (30.7% with high-grade dysplasia), and 90.4% specificity for advanced colorectal neoplasia. With approval, the test meets Medicare coverage criteria and is expected to be named in American Cancer Society guidelines, supporting broader access.
Under an August 2025 commercial agreement, Abbott will exclusively commercialize SimpleScreen CRC in the U.S. and will pay Freenome a $100 million milestone tied to this FDA approval. The product is the first commercial milestone in Freenome’s Personalized Cancer Detection strategy and will be integrated into its broader SimpleScreen portfolio and multiomics-based pipeline.
Freenome, Inc. reported that former director Kenneth Song converted 30,000 Class B Ordinary Shares into 30,000 shares of Common Stock on July 20, 2026, in connection with its business combination with Old Freenome. After these conversions, he holds 30,000 Common shares and no remaining Class B shares.
Freenome, Inc., the Delaware successor to Perceptive Capital Solutions Corp. (PCSC), filed a post-effective amendment to its Form S-4 registration statement under Rule 414(d) to reflect its Domestication, name change and completion of a business combination with Freenome Holdings, Inc. PCSC continued out of the Cayman Islands and domesticated into Delaware under Section 388 of the DGCL, changing its name to Freenome, Inc.
In the Domestication, PCSC redeemed public Class A shares validly submitted for redemption, converted each Class B share into a Class A share on a one-for-one basis, and then converted each outstanding Class A share into one share of New Freenome common stock. Trading of New Freenome common stock on Nasdaq began on July 21, 2026 under ticker “FRNM”. The amendment also describes New Freenome’s expanded director and officer indemnification arrangements under Delaware law and confirms that no additional securities are being registered and no further registration fee is required.
Freenome, Inc., formerly Perceptive Capital Solutions Corp., completed its business combination and domestication on July 20, 2026, ceasing to be a shell company and becoming the public parent of Freenome Holdings, Inc. Its common stock now trades on the Nasdaq Capital Market under the symbol FRNM.
New Freenome received gross proceeds of approximately $310.3 million in connection with the transaction, including $70.3 million from PCSC’s trust account and $240.0 million from a PIPE in which investors purchased 24,000,000 shares at $10.00 per share. Holders of 1,392,723 Class A shares redeemed at about $10.82 per share for roughly $15.1 million. Pro forma securities outstanding include 68,065,429 shares issued to former Freenome stockholders, 6,478,269 to PCSC shareholders, 2,442,500 to the sponsor and initial shareholders, plus options on 8,272,601 shares and RSUs on 4,034,512 shares. Shares of New Freenome common stock issued and outstanding totaled 107,446,814 as of the Closing Date.
An Investor Rights Agreement and PIPE subscription agreements provide registration rights covering about 65,440,613 shares, representing approximately 60.9% of outstanding common stock, and key holders are subject to a six‑month lock‑up. New Freenome adopted a 2026 Equity Incentive Plan initially reserving 14,773,227 shares (with an automatic 5% annual increase feature) and a 2026 Employee Stock Purchase Plan initially reserving 2,462,204 shares with capped annual increases. A new Executive Severance Plan, updated charter and bylaws, a staggered seven‑member board, and auditor transition to EY were also put in place. Major holders include Roche at 17.4%, RA Capital at 14.3%, Perceptive Life Sciences Master Fund at 12.4%, Andreessen Horowitz at 5.2%, and directors and officers as a group at 4.7%.
Perceptive Capital Solutions Holdings, a former 10% owner of Freenome, Inc., reported the conversion of 2,066,250 Class B Ordinary Shares into the same number of shares of Common Stock on July 20, 2026 in connection with Freenome's business combination with Old Freenome. Following the one-for-one conversions, the reporting person holds 2,352,500 shares of Common Stock directly, and its two directors, Adam Stone and Michael Altman, share voting and investment discretion over these securities. The transactions were not executed under a Rule 10b5-1 trading plan.
Perceptive Advisors LLC, together with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., reports beneficial ownership of Freenome, Inc. Common Stock on a Schedule 13G. The Master Fund directly holds 10,871,847 shares of Common Stock, and each Reporting Person may be deemed to beneficially own these shares.
The ownership represents 10.1% of Freenome’s Common Stock, based on 107,446,814 shares outstanding as of July 20, 2026 as reported by the issuer. Each Reporting Person has 0 shares with sole voting or dispositive power and 10,871,847 shares with shared voting and shared dispositive power.